Trial Profile
An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs QN 165 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 Feb 2011 Status changed from recruiting to discontinued, according to an Antisoma media release.
- 01 Feb 2011 Additional location [Taiwan] identified as reported by ClinicalTrials.gov.
- 13 Oct 2010 Results are expected in the first half of 2011.